GoodRx (NASDAQ:GDRX) Shares Gap Down to $8.39

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) gapped down before the market opened on Tuesday . The stock had previously closed at $8.39, but opened at $8.21. GoodRx shares last traded at $8.25, with a volume of 44,393 shares trading hands.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Barclays increased their price objective on shares of GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Monday, May 20th. The Goldman Sachs Group increased their price objective on shares of GoodRx from $6.50 to $7.50 and gave the company a “neutral” rating in a research report on Friday, March 1st. Truist Financial increased their price objective on shares of GoodRx from $7.50 to $8.00 and gave the company a “hold” rating in a research report on Friday, March 1st. UBS Group raised their price target on shares of GoodRx from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, March 1st. Finally, Wells Fargo & Company raised shares of GoodRx from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $7.50 to $10.00 in a report on Monday, March 25th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.32.

GoodRx Trading Down 2.7 %

The company’s 50 day moving average price is $7.43 and its two-hundred day moving average price is $6.87. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 1.02.

GoodRx (NASDAQ:GDRX) last released its earnings results on Thursday, May 9th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The firm had revenue of $197.88 million for the quarter, compared to the consensus estimate of $196.20 million. As a group, analysts expect that GoodRx Holdings, Inc. will post 0.17 EPS for the current fiscal year.

Institutional Investors Weigh In On GoodRx

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of GoodRx by 2.1% during the third quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company’s stock valued at $48,875,000 after buying an additional 177,961 shares during the last quarter. Rubric Capital Management LP bought a new stake in shares of GoodRx during the fourth quarter valued at approximately $39,348,000. Rip Road Capital Partners LP raised its position in shares of GoodRx by 25.8% during the fourth quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock valued at $11,814,000 after buying an additional 361,294 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of GoodRx during the third quarter valued at approximately $8,866,000. Finally, Assenagon Asset Management S.A. raised its position in shares of GoodRx by 7.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,349,800 shares of the company’s stock valued at $9,044,000 after buying an additional 99,072 shares during the last quarter. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.